These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15758701)

  • 1. Tolterodine for the treatment of daytime incontinence in children.
    Greenfield SP
    J Urol; 2005 Apr; 173(4):1064. PubMed ID: 15758701
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
    Nijman RJ; Borgstein NG; Ellsworth P; Djurhuus JC
    J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Wein AJ
    J Urol; 2005 Jun; 173(6):2056-7. PubMed ID: 15879827
    [No Abstract]   [Full Text] [Related]  

  • 4. [A meta-analysis documenting the optimal tolerance profile of tolterodine].
    Rev Med Suisse; 2006 May; 2(65):1234. PubMed ID: 16767876
    [No Abstract]   [Full Text] [Related]  

  • 5. Tolterodine.
    Nurs Times; 2006 Jun 6-12; 102(23):27. PubMed ID: 16784047
    [No Abstract]   [Full Text] [Related]  

  • 6. PHARMAC responds on tolterodine for overactive bladder.
    Moodie P
    N Z Med J; 2005 Feb; 119(1229):U1871. PubMed ID: 16498471
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
    Athanasopoulos AA; Perimenis PS
    BJU Int; 2005 May; 95(7):1117-8. PubMed ID: 15839945
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
    Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z
    BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Overactive bladder. New anticholinergic drug controls urinary urge].
    MMW Fortschr Med; 2004 Jul; 146(27-28):51. PubMed ID: 15526670
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
    Jonas U; Rackley RR
    Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
    [No Abstract]   [Full Text] [Related]  

  • 14. [Less disability in daily activities].
    Krankenpfl J; 2005; 43(7-10):191. PubMed ID: 16515263
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolterodine for treatment of overactive bladder.
    Kanofsky JA; Nitti VW
    Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatment of overactive bladder.
    Rackley R; Wein A; Nelson D
    Mayo Clin Proc; 2001 Nov; 76(11):1179-80. PubMed ID: 11702910
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P; Kaplan S; De Koning Gans HJ; Millard R
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with overactive bladders deserve better.
    Brenner B; Rice M
    N Z Med J; 2006 Feb; 119(1229):U1846. PubMed ID: 16498474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.